(ANSA) - FLORENCE, NOV 12 - "Our forecasts are to have this monoclonar ready for use in March 2021. For now, all things are going according to these times, it is clear that we are doing research and development, and in this sector know that failures and delays are always possible but we try to avoid them ".
This was stated by RinoRappuoli, scientific director of Gsk Vaccines and coordinator of the research project on monoclonal antibodies at ToscanaLife Sciences on the occasion of the delivery of the Golden Pegasus by the Tuscany Region.
Rino Rappuoli then added that Tls plans to "make a few million doses per year" in the "Menarini plants.
Technology and research generate products and products generate skilled jobs "." So what I see - he concluded - is not just this drug, but a chain that if we invest well, if we can build on these foundations that we build we will create many jobs ". (ANSA).
